The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.
UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib
FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis